ArticleMedicine2016
Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion.
Article in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Sequential Pleural Fluid and Serum Biomarker Measurements in Patients Undergoing Medical Thoracoscopy for Persistently Undiagnosed Pleural Effusion: A Pilot Study from a TB-Endemic Tertiary Centre.Pulmonary therapy · 2026Article
- Bacteriology and clinical outcomes of pleural infections in Singapore: an 8-year retrospective observational study.Journal of thoracic disease · 2026Article
- Pleural Metastatic Melanoma with Refractory Hemorrhagic Effusion: A Case Report.Cancer management and research · 2026Article
- Risk factors for refractory malignant pleural effusion and the impact on prognosis in non-small cell lung cancer patients with advanced EGFR mutations: a retrospective cohort study using propensity score matching.Translational cancer research · 2025Article
- Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion.BMC cancer · 2025Article
- Diagnostic value of monocyte chemoattractant protein-1 (MCP-1) and lactate dehydrogenase (LDH) in malignant pleural effusion: A cross-sectional study.Lung India : official organ of Indian Chest Society · 2025Article
- A novel bioassay reflecting response to immune checkpoint inhibitor therapy in non-small cell lung cancer with malignant pleural effusion.Translational lung cancer research · 2024Article
- Development of a diagnostic algorithm to ascertain malignant pleural effusion utilizing clinical indicators and serum metal concentrations.Frontiers in oncology · 2024Article
- Development and validation of the CAIL prognostic score in non-small cell lung cancer patients with malignant pleural effusion.The clinical respiratory journal · 2023Article
- Risk factors for symptomatic malignant pleural effusion recurrence in patients with actionable mutations in advanced lung adenocarcinoma.Translational lung cancer research · 2023Article
- Pleural Fluid Resolution Is Associated with Improved Survival in Patients with Malignant Pleural Effusion.Life (Basel, Switzerland) · 2023Article
- Serum lactate dehydrogenase activities as systems biomarkers for 48 types of human diseases.Scientific reports · 2021Article
- A retrospective study on the combined biomarkers and ratios in serum and pleural fluid to distinguish the multiple types of pleural effusion.BMC pulmonary medicine · 2021Article
- Development of RECLS score to predict survival in lung cancer patients with malignant pleural effusion.Translational lung cancer research · 2021Article
- Total Protein-Chloride Ratio in Pleural Fluid Independently Predicts Overall Survival in Malignant Pleural Effusion at the First Diagnosis.Frontiers in oncology · 2021Article
- Prognostic value of a new score using serum alkaline phosphatase and pleural effusion lactate dehydrogenase for patients with malignant pleural effusion.Thoracic cancer · 2020Observational
- Pleural effusion as an isolated finding in COVID-19 infection.Respiratory medicine case reports · 2020Article
- Interpreting pleural fluid results .Clinical medicine (London, England) · 2019Review
- Prognostic Significance of Blood, Serum, and Ascites Parameters in Patients with Malignant Peritoneal Mesothelioma or Peritoneal Carcinomatosis.Gastroenterology research and practice · 2018Article
- The pleural fluid lactate dehydrogenase/adenosine deaminase ratio differentiates between tuberculous and parapneumonic pleural effusions.BMC pulmonary medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To study the performance of serum and pleural lactate dehydrogenase (LDH) level in predicting survival in patients with adenocarcinoma lung presenting with malignant pleural effusions (MPE) at initial diagnosis.Retrospective cohort study of the patient hospitalized for adenocarcinoma lung with MPE in year 2012.Univariate analyses showed lower pleural fluid LDH 667 (313-967) versus 971 (214-3800), P = 0.04, female gender 9 (100%) versus 27 (41.5%), P = 0.009, never smoking status 9 (100%) versus 36 (55.3%), P = 0.009, and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy 8 (89%) versus 26 (40%), P = 0.009 to correlate with survival of more than 1.7 year versus less than 1.7 year. In multivariate analysis, low pleural fluid LDH and female gender maintained significance. The pleural LDH level of ≤1500 and >1500 U/L discriminated significantly (P = 0.009) between survival.High pleural LDH (>1500 IU/L) predicts shorter survival (less than a year) in patients with adenocarcinoma lung presenting with MPE at the time of initial diagnosis. This marker may be clinically applied for selecting therapeutic modality directed at prevention of reaccumulation of MPE. Patients with low pleural LDH may be considered suitable for measures that provide more sustained effect on prevention of reaccumulation such as chemical pleurodesis or tunneled pleural catheter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.